Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that
currently combines the selectivity of monoclonal antibodies with the potency of a payload …

An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which
results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously …

Since the first approval of gemtuzumab ozogamicin (Mylotarg; Pfizer; CD33 targeted), two
additional antibody–drug conjugates (ADC), brentuximab vedotin (Adcetris; Seattle …

Cancer remains the leading cause of death worldwide despite advances in treatment
options for patients. As such, safe and effective therapeutics are required. Short peptides …

Abstract Antibody Drug Conjugate (ADC) is an emerging technology to overcome the
limitations of chemotherapy by selectively targeting the cancer cells. ADC binds with an …

In spite of the successful use of monoclonal antibodies (mAbs) in clinic for tumor treatment,
their applications are still hampered in therapeutic development due to limitations, such as …

Building upon the resounding therapeutic success of monoclonal antibodies, and supported
by accelerating progress in engineering methods, the field of multispecific therapeutic …

The targeted delivery of potent cytotoxic molecules into cancer cells is considered a
promising anticancer strategy. The design of clinically effective antibody–drug conjugates …

Genetic encoding of noncanonical amino acid (ncAA) for site-specific protein modification
has been widely applied for many biological and therapeutic applications. To efficiently …

Nanobodies (Nb) have a promising future as a part of next generation chemodrug delivery
systems. Nb, or VHH, are small (15 kDa) monomeric antibody fragments consisting of the …